NasdaqCM:ABEOBiotechs
Abeona Therapeutics (ABEO): Assessing Value After J-Code Milestone for ZEVASKYN Approval
Abeona Therapeutics (ABEO) just announced that the Centers for Medicare and Medicaid Services has established a permanent J-code for ZEVASKYN, its gene therapy for RDEB. The code takes effect in January 2026, making billing and access for providers more efficient.
See our latest analysis for Abeona Therapeutics.
Even with this major regulatory milestone for ZEVASKYN, Abeona Therapeutics’ share price return has been under pressure, with a 30-day retreat of 22.2% and a year-to-date slide of...